Is this Journal Legitimate?

Every now and then someone forwards an email from a publisher inviting him or her or them to review submissions, submit an article, or be on the editorial board of a journal. I start reading and three things jump out at me:

  • Reputable journals and conferences don’t email you out of the blue.
  • This email is not very well written.
  • Considering that the representative from this journal is contacting this clinician/researcher for the first time, it’s very informal.

There have been unscrupulous publishers for as long as there have been publishers. They are in the minority but their numbers are growing, and they are becoming more sophisticated. The following are some of the things we look for:

The Journal

  • Does the journal have an valid ISSN?
    • Why does this matter? When a publisher applies for an ISSN, they must provide information and supporting documentation to the ISSN International Centre including: title, frequency, publisher’s name, and medium along with copies of the title page, cover page, editorial page, PDF or JPG of the jacket (if the publication is on CD-ROM), and the URL if the journal is online. Publishers can apply for an ISSN in advance of publication. If the journal does not have an ISSN, be wary of the publisher.
  • Is the current issue available online?
    • Are any back issues available online? If so, does the content look credible? Do you recognize any of the authors?
  • Are their copyright policies, open access policies (where applicable), and peer-review policies and processes explained clearly?
    • More and more predatory journals are putting these policies online. Make sure they make sense and weigh them carefully against other factors, like lacking an ISSN.
  • If the journal boasts an Impact Factor or an Eigenfactor, can it be verified through Journal Citation Reports or Eigenfactor.org, respectively?
    • The Talbot Library subscribes to Journal Citation Reports. The Eigenfactor can be verified at Eigenfactor.org.
  • If the journal claims to be indexed in a particular database (PubMed, Web of Science, SCOPUS, EMBASE) search any or all of those databases to verify the claim.
    • Unscrupulous publishers have been known to create false indexes and claim their journal is indexed there. Something else to keep in mind is every once in a while an article from a predatory journal does make its way into a database.

The Publisher

  • Does the publisher provide full, verifiable contact information including the street address, a working email address, and a working telephone number either in the email message or on the Web site?
    • If you are unsure of the publisher’s veracity, you are well within your rights to phone or email. I prefer phoning, myself. Last time I phoned a questionable publisher, I was bounced into a random, numbered voicemail.
  • If the journal charges publication fees, are they stated up-front and explained clearly?
  • Does the publisher have a Web site? Are the pages within that site stable?
  • On the Web site, check for language use, grammatical errors, and typographical errors. Is the language stilted? Overly formal? Strangely inappropriate?
    • I once ran across a publisher who took great pains to state that they were an American publishing organization, as opposed to an American publisher. Yet they used the British spelling of gynecological.
    • This same publisher described a nursing journal as follows, “Nursing, the word itself reflects a “care” in it and can be treated as the most divine and dedicated professional science that helps patients in the severely ill circumstances from the time of birth till death.”
  • Is the publisher listed in Ulrich’s or  SHERPA/Romeo?
    • Ulrich’s and SHERPA/Romeo will tell you where a publisher is headquartered, where a journal is indexed, how often new issues are released (frequency), and more. SHERPA/Romeo is available free online but ask one of us in the library to search Ulrich’s.

What can I do?

  • Be very wary of unsolicited contact from a publisher with whom you are not familiar.
  • Don’t agree to review submissions, submit articles, or join an editorial board of a journal you do not recognize.
  • Check any claims made by the publisher, be they impact factor, member of an editorial board, or incluion in an index or database like Web of Science or PubMed.
  • Keep your online presence current and accurate.
    • Keeping your professional information up to date makes it easier for others to do the due diligence when they are researching a suspect journal.
  • Have you been fooled by a predatory publisher, tell your colleagues.
  • When in doubt about a journal, publisher, or conference, talk to a librarian.
    • Librarians are trained to find and evaluate information. If you have doubts come talk to us, we can look into the publisher for you.
Advertisements

Staff Publications: September 2017

    1. Alter H, Block TM, Brown N, et al. A Research Agenda for Curing Chronic Hepatitis B Virus Infection. Hepatology. 2017. PMID: 28877549.
    2. Brown PA, Shah B, Fathi A, et al. Nccn Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2017;15(9):1091-1102. PMID: 28874594.
    3. Cahn DB, Ristau BT, Ghiraldi EM, et al. Bladder Preservation Therapy: A Review of the Literature and Future Directions. Urology. 2016;96:54-61. PMID: 27257135.
    4. Carroll PR, Parsons JK, Andriole G, et al. Nccn Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. J Natl Compr Canc Netw. 2016;14(5):509-519. PMID: 27160230.
    5. Churilla TM, Ballman KV, Brown PD, et al. Stereotactic Radiosurgery with or without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial. Int J Radiat Oncol Biol Phys. 2017. PMID: 28939223.
    6. Churilla TM, Handorf E, Collette S, et al. Whole Brain Radiotherapy after Stereotactic Radiosurgery or Surgical Resection among Patients with One to Three Brain Metastases and Favorable Prognoses: A Secondary Analysis of Eortc 22952-26001. Ann Oncol. 2017;28(10):2588-2594. PMID: 28961826.
    7. Clark PE, Spiess PE, Agarwal N, et al. Nccn Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016;14(10):1213-1224. PMID: 27697976. PMC5379654. NIHMS852988.
    8. de Oliveira JF, Lima TS, Vendramini-Costa DB, et al. Thiosemicarbazones and 4-Thiazolidinones Indole-Based Derivatives: Synthesis, Evaluation of Antiproliferative Activity, Cell Death Mechanisms and Topoisomerase Inhibition Assay. Eur J Med Chem. 2017;136:305-314. PMID: 28505535.
    9. Deng N, Flynn WF, Xia J, et al. Large Scale Free Energy Calculations for Blind Predictions of Protein-Ligand Binding: The D3r Grand Challenge 2015. J Comput Aided Mol Des. 2016;30(9):743-751. PMID: 27562018.
    10. Denlinger CS, Sanft T, Baker KS, et al. Survivorship, Version 2.2017: Clinical Practice Guidelines in Oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2017;15(9):1140-1163.
    11. Dubey B, Jackson M, Zeigler-Johnson C, et al. Inflammation Polymorphisms and Prostate Cancer Risk in Jamaican Men: Role of Obesity/Body Size. Gene. 2017. PMID: 28903065.
    12. Edwards DC, Cahn DB, Smaldone MC, Kutikov A. Use of Administrative Data for Comparative Effectiveness Research in the Treatment of Non-Prostate Genitourinary Malignancies. Urol Oncol. 2017. PMID: 28867432.
    13. Esposito AC, Crawford J, Sigurdson ER, et al. Omission of Radiotherapy after Breast Conservation Surgery in the Postneoadjuvant Setting. Journal of Surgical Research. 2018;221:49-57.
    14. Finnberg NK, Gokare P, Lev A, et al. Application of 3d Tumoroid Systems to Define Immune and Cytotoxic Therapeutic Responses Based on Tumoroid and Tissue Slice Culture Molecular Signatures. Oncotarget. 2017;8(40):66747-66757.
    15. Fortner RT, Schock H, Jung S, et al. Anti-Mullerian Hormone and Endometrial Cancer: A Multi-Cohort Study. Br J Cancer. 2017. PMID: 28873086.
    16. Ginzburg S, Tomaszewski JJ, Kutikov A. Focal Ablation Therapy for Renal Cancer in the Era of Active Surveillance and Minimally Invasive Partial Nephrectomy. Nat Rev Urol. 2017. PMID: 28895562.
    17. Guitarte C, Grant J, Zhao H, Wang S, Ferriss JS, Hernandez E. Incisional Hernia Formation and Associated Risk Factors on a Gynecologic Oncology Service: An Exploratory Analysis. Arch Gynecol Obstet. 2016;294(4):805-811. PMID: 27101367.
    18. Gupta MK, Tahrir FG, Knezevic T, et al. Grp78 Interacting Partner Bag5 Responds to Er Stress and Protects Cardiomyocytes from Er Stress-Induced Apoptosis. J Cell Biochem. 2016;117(8):1813-1821. PMID: 26729625. PMC4909508. NIHMS778644.
    19. Haifler M, Ristau BT, Higgins AM, et al. External Validation of Contact Surface Area as a Predictor of Post-Operative Renal Function in Patients Undergoing Partial Nephrectomy. J Urol. 2017. PMID: 28941921.
    20. Hayakawa K, Formica AM, Zhou Y, et al. Nlr Nod1 Signaling Promotes Survival of Bcr-Engaged Mature B Cells through up-Regulated Nod1 as a Positive Outcome. J Exp Med. 2017;214(10):3067-3083. PMID: 28878001. PMC5626402.
    21. Herceg Z, Ghantous A, Wild CP, et al. Roadmap for Investigating Epigenome Deregulation and Environmental Origins of Cancer. Int J Cancer. 2017.
    22. Huepenbecker SP, Divine L, Chu CS, Mutch DG. Two Sisters with Mayer-Rokitansky-Kuster-Hauser Syndrome and Serous Adenocarcinoma of the Ovary. Gynecol Oncol Rep. 2017;22:13-15. PMID: 28932808. PMC5596329.
    23. Isoda T, Moore AJ, He Z, et al. Non-Coding Transcription Instructs Chromatin Folding and Compartmentalization to Dictate Enhancer-Promoter Communication and T Cell Fate. Cell. 2017;171(1):103-119.e118. PMID: 28938112. PMC5621651. NIHMS904268.
    24. Jain R, Dotan E. Nutrition and Aging: A Practicing Oncologist’s Perspective. Curr Oncol Rep. 2017;19(11):71. PMID: 28884400.
    25. Jordan SE, Micaily I, Hernandez E, et al. Image-Guided High-Dose-Rate Intracavitary Brachytherapy in the Treatment of Medically Inoperable Early-Stage Endometrioid Type Endometrial Adenocarcinoma. Brachytherapy. 2017. PMID: 28958736.
    26. Jung S, Allen N, Arslan AA, et al. Anti-Mullerian Hormone and Risk of Ovarian Cancer in Nine Cohorts. Int J Cancer. 2017. PMID: 28921520.
    27. Krais JJ, Virani N, McKernan PH, et al. Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide. Molecular Cancer Therapeutics. 2017;16(9):1855-1865.
    28. Lev A, Deihimi S, Shagisultanova E, et al. Preclinical Rationale for Combination of Crizotinib with Mitomycin C for the Treatment of Advanced Colorectal Cancer. Cancer Biol Ther. 2017:1-11. PMID: 28886275.
    29. Lu H, Liu S, Zhang G, et al. Pak Signalling Drives Acquired Drug Resistance to Mapk Inhibitors in Braf-Mutant Melanomas. Nature. 2017;550(7674):133-136. PMID: 28953887.
    30. Merza H, Bilusic M. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Curr Oncol Rep. 2017;19(4):27. PMID: 28303494.
    31. Moore MD, Daly JM. The Evolution of Oncology Clinical Research: Lessons Learned. Surg Oncol Clin N Am. 2017;26(4):xvii-xx. PMID: 28923234.
    32. Mortazavi SMJ. Comments on “Study of Bacterial Contamination of Mobile Phones and Stethoscopes in Neonatal Intensive Care Unit”. International Journal of Pediatrics. 2017;5(11):6143-6144.
    33. Mortazavi SMJ. Re: Are Electromagnetic Fields in Incubators a Risk Factor for Autism? Acta Paediatr. 2017. PMID: 28862780.
    34. Ndoye A, Budina-Kolomets A, Kugel CH, et al. Atg5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma. Cancer Res. 2017. PMID: 28887323.
    35. Pal RK, Haider K, Kaur D, et al. A Combined Treatment of Hydration and Dynamical Effects for the Modeling of Host-Guest Binding Thermodynamics: The Sampl5 Blinded Challenge. J Comput Aided Mol Des. 2017;31(1):29-44. PMID: 27696239. PMC5477994. NIHMS864064.
    36. Parker DC, Handorf E, Smaldone MC, Uzzo RG, Pitt H, Reese AC. Race and Postoperative Complications Following Urologic Cancer Surgery: An Acs-Nsqip Analysis. Urol Oncol. 2017. PMID: 28867431.
    37. Ramos JD, Wingate JT, Gulati R, et al. Venous Thromboembolism Risk in Patients with Locoregional Urothelial Tract Tumors. Clin Genitourin Cancer. 2017. PMID: 28923700.
    38. Reck M, Paz-Ares L, Bidoli P, et al. Outcomes in Patients with Aggressive or Refractory Disease from Revel: A Randomized Phase Iii Study of Docetaxel with Ramucirumab or Placebo for Second-Line Treatment of Stage Iv Non-Small-Cell Lung Cancer. Lung Cancer. 2017;112:181-187.
    39. Ribas A, Dummer R, Puzanov I, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-Pd-1 Immunotherapy. Cell. 2017;170(6):1109-1119.e1110. PMID: 28886381.
    40. Rossiter SE, Fletcher MH, Wuest WM. Natural Products as Platforms to Overcome Antibiotic Resistance. Chem Rev. 2017. PMID: 28953368.
    41. Shore ND, Dinney C, Uzzo R. The Society of Urologic Oncology Clinical Trials Consortium: A Brief History and Overview. Rev Urol. 2017;19(2):122-124. PMID: 28959150. PMC5610363.
    42. Sigurdson ER. Preface. Surg Oncol Clin N Am. 2017;26(4):xv-xvi. PMID: 28923233.
    43. Ward JM, Schmalenberg K, Antonishyn NA, et al. Human Papillomavirus Genotype Distribution in Cervical Samples among Vaccine Naive Barbados Women. Cancer Causes Control. 2017. PMID: 28913693.
    44. Werlang ME, Lewis MD, Bartel MJ. Tumor Necrosis Factor Alpha Inhibitor-Induced Acute Pancreatitis. ACG Case Rep J. 2017;4:e103. PMID: 28879208. PMC5577046.
    45. Wu D, Si M, Xue HY, Wong HL. Nanomedicine Applications in the Treatment of Breast Cancer: Current State of the Art. Int J Nanomedicine. 2017;12:5879-5892. PMID: 28860754. PMC5566389.
    46. Zhang BW, Deng N, Tan Z, Levy RM. Stratified Uwham and Its Stochastic Approximation for Multicanonical Simulations Which Are Far from Equilibrium. J Chem Theory Comput. 2017. PMID: 28902500.

     

Staff Publications: August 2017

  1. Abouassaly R, Bream MJ, Smaldone MC, et al. National Utilization of Regional Lymph Node Dissection among Patients with Kidney Cancer and Clinical Lymphadenopathy Undergoing Radical Nephrectomy. Cancer Treatment and Research Communications. 2017;12:14-18.
  2. Alpaugh RK, Zhou LL, Dicker DT, Matthew E, El-Deiry WS. Circulating Tumor Cells: Silent Predictors of Metastasis. F1000Research. 2017;6.
  3. Alvarez P, Jensen LE. Imiquimod Treatment Causes Systemic Disease in Mice Resembling Generalized Pustular Psoriasis in an Il-1 and Il-36 Dependent Manner. Mediators Inflamm. 2016;2016:6756138. PMID: 28057979. PMC5183767.
  4. An Y, Doney AC, Andrade RB, Wheeler SE. Stacking Interactions between 9-Methyladenine and Heterocycles Commonly Found in Pharmaceuticals. J Chem Inf Model. 2016;56(5):906-914. PMID: 27074615.
  5. Anthony SA, Burrell AL, Johnson MC, et al. Reconstituted Impdh Polymers Accommodate Both Catalytically Active and Inactive Conformations. Mol Biol Cell. 2017. PMID: 28794265.
  6. Astsaturov I. Future Clinical Trials. Genetically Driven Trials. Surgical Oncology Clinics of North America. 2017.
  7. Belinsky MG, Cai KQ, Zhou Y, et al. Succinate Dehydrogenase Deficiency in a Pdgfra Mutated Gist. BMC Cancer. 2017;17(1):512. PMID: 28768491. PMC5541693.
  8. Boland PM, Meyer JE, Berger AC, et al. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (Zd6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol. 2017;40(4):393-398. PMID: 26986978. PMC5026539. NIHMS640074.
  9. Boyle SM, Ali N, Olszanski AJ, et al. Donor-Derived Metastatic Melanoma and Checkpoint Inhibition. Transplant Proc. 2017;49(7):1551-1554. PMID: 28838438.
  10. Cahn DB, Handorf E, Ristau BT, et al. Contemporary Practice Patterns and Survival Outcomes for Locally Advanced Urethral Malignancies: A National Cancer Database Analysis. Urol Oncol. 2017. PMID: 28803701.
  11. Chakhtoura M, Sriram U, Heayn M, et al. Bisphenol a Does Not Mimic Estrogen in the Promotion of the in Vitro Response of Murine Dendritic Cells to Toll-Like Receptor Ligands. Mediators Inflamm. 2017;2017:2034348. PMID: 28811679. PMC5547709.
  12. Chen VS, Abouassaly R, Gonzalez CM, et al. Association of Race and Margin Status among Patients Undergoing Robotic Partial Nephrectomy for T1 Renal Cell Carcinoma: Results from a Population-Based Cohort. Urol Oncol. 2017. PMID: 28781110.
  13. Dalton BGA, Friedant AJ, Su S, Schatz TAP, Ruth KJ, Scott WJ. Benefits of Supplemental Jejunostomy Tube Feeding During Neoadjuvant Therapy in Patients with Locally Advanced, Potentially Resectable Esophageal Cancer. J Laparoendosc Adv Surg Tech A. 2017. PMID: 28777676.
  14. Dans M, Smith T, Back A, et al. Nccn Guidelines Insights: Palliative Care, Version 2.2017. J Natl Compr Canc Netw. 2017;15(8):989-997. PMID: 28784860.
  15. Di Meco A, Li JG, Blass BE, Abou-Gharbia M, Lauretti E, Pratico D. 12/15-Lipoxygenase Inhibition Reverses Cognitive Impairment, Brain Amyloidosis, and Tau Pathology by Stimulating Autophagy in Aged Triple Transgenic Mice. Biol Psychiatry. 2017;81(2):92-100. PMID: 27499089.
  16. 16. Diez PJG, Su YR, Russo J. Immunocytochemical Stem Cell Markers Can Predict Clinical Stage of Breast Cancer. Oncology Reports. 2017;38(3):1507-1516.
  17. Dong Y, Li T, Churilla TM, et al. Impact of Rheumatoid Arthritis on Radiation-Related Toxicity and Cosmesis in Breast Cancer Patients: A Contemporary Matched-Pair Analysis. Breast Cancer Res Treat. 2017. PMID: 28825145.
  18. Dotan E. Advancing Treatment Approach to the Older Patient with Cancer through Clinical Trials Participation. Surgical Oncology Clinics of North America. 2017.
  19. Dotan E, Cohen SJ, Starodub AN, et al. Phase I/Ii Trial of Labetuzumab Govitecan (Anti-Ceacam5/Sn-38 Antibody-Drug Conjugate) in Patients with Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017:Jco2017739011. PMID: 28817371.
  20. Epperla N, Maddocks KJ, Salhab M, et al. C-Myc-Positive Relapsed and Refractory, Diffuse Large B-Cell Lymphoma: Impact of Additional “Hits” and Outcomes with Subsequent Therapy. Cancer. 2017.
  21. Fakhry C, Zhang Q, Nguyen-Tan PF, et al. Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients with Oropharyngeal Cancer. J Clin Oncol. 2017:Jco2016720748. PMID: 28777690.
  22. Finelli A, Ismaila N, Bro B, et al. Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(6):668-680. PMID: 28095147.
  23. Goel N, Reddy SS. Randomized Clinical Trials in Pancreatic Cancer. Surgical Oncology Clinics of North America. 2017.
  24. Gokare P, Finnberg NK, Abbosh PH, Dai J, Murphy ME, El-Deiry WS. P53 Represses Pyrimidine Catabolic Gene Dihydropyrimidine Dehydrogenase (Dpyd) Expression in Response to Thymidylate Synthase (Ts) Targeting. Sci Rep. 2017;7(1):9711. PMID: 28851987.
  25. Gokare P, Lulla AR, El-Deiry WS. Mmr-Deficiency and Brca2/Egfr/Ntrk Mutations. Aging (Albany NY). 2017. PMID: 28783711.
  26. Gupta MK, Kaminski R, Mullen B, et al. Hiv-1 Nef-Induced Cardiotoxicity through Dysregulation of Autophagy. Sci Rep. 2017;7(1):8572. PMID: 28819214. PMC5561171.
  27. Hall MJ, Forman AD, Obeid E. The Hereditary Paraganglioma-Pheochromocytoma Syndrome: No Time to Waste. JAMA Oncol. 2017. PMID: 28837713.
  28. Hoang TM, Kent T, Pomerantz RT. Modification of 3′ Terminal Ends of DNA and Rna Using DNA Polymerase Theta Terminal Transferase Activity. Bio Protoc. 2017;7(12). PMID: 28824932. PMC5560110. NIHMS888405.
  29. Huo J, Chu Y, Chamie K, et al. Increased Utilization of Positron Emission Tomography/Computed Tomography (Pet/Ct) Imaging and Its Economic Impact for Patients Diagnosed with Bladder Cancer. Clin Genitourin Cancer. 2017. PMID: 28826932.
  30. Jalal SI, Hanna N, Zon R, et al. Phase I Study of Amrubicin and Cyclophosphamide in Patients with Advanced Solid Organ Malignancies: Hog Lun 07-130. American Journal of Clinical Oncology-Cancer Clinical Trials. 2017;40(4):329-335.
  31. Jensen LE. Interleukin-36 Cytokines May Overcome Microbial Immune Evasion Strategies That Inhibit Interleukin-1 Family Signaling. Sci Signal. 2017;10(492). PMID: 28811383.
  32. Kantarjian HM, Roboz GJ, Kropf PL, et al. Guadecitabine (Sgi-110) in Treatment-Naive Patients with Acute Myeloid Leukaemia: Phase 2 Results from a Multicentre, Randomised, Phase 1/2 Trial. Lancet Oncol. 2017. PMID: 28844816.
  33. Kearns A, Gordon J, Burdo TH, Qin X. Hiv-1-Associated Atherosclerosis: Unraveling the Missing Link. J Am Coll Cardiol. 2017;69(25):3084-3098. PMID: 28641798. PMC5512584. NIHMS876379.
  34. Lee M, Zhu L, Wang MQ, et al. Psychosocial Predictors of Hbv Screening Behavior among Vietnamese Americans. Am J Health Behav. 2017;41(5):561-570. PMID: 28760178.
  35. Li K, Wen M, Henry KA. Ethnic Density, Immigrant Enclaves, and Latino Health Risks: A Propensity Score Matching Approach. Soc Sci Med. 2017;189:44-52. PMID: 28780439. PMC5573190. NIHMS897740.
  36. Liu Y, von Mehren M. Randomized Clinical Trials in Gastrointestinal Stromal Tumors. Surgical Oncology Clinics of North America. 2017.
  37. Lucas JW, Lester KM, Chen A, Simhan J. Scrotal Reconstruction and Testicular Prosthetics. Translational Andrology and Urology. 2017;6(4):710-721.
  38. Lynch SM, Mitra N, Ross M, et al. A Neighborhood-Wide Association Study (NWAS): Example of Prostate Cancer Aggressiveness. PLoS One. 2017;12(3):e0174548. PMID: 28346484. PMC5367705.
  39. Maggiore RJ, Dale W, Hurria A, et al. Hematology-Oncology Fellows’ Training in Geriatrics and Geriatric Oncology: Findings from an American Society of Clinical Oncology-Sponsored National Survey. J Oncol Pract. 2017:Jop2017022111. PMID: 28837375.
  40. Martin LP, Konner JA, Moore KN, et al. Characterization of Folate Receptor Alpha (Fralpha) Expression in Archival Tumor and Biopsy Samples from Relapsed Epithelial Ovarian Cancer Patients: A Phase I Expansion Study of the Fralpha-Targeting Antibody-Drug Conjugate Mirvetuximab Soravtansine. Gynecol Oncol. 2017. PMID: 28843653.
  41. Mortazavi SMJ, Bevelacqua JJ, Corrice L, et al. Comment on “Chromosomal Aberrations in Large Japanese Field Mice (Apodemus Speciosus) Captured near Fukushima Dai-Ichi Nuclear Power Plant”. Environmental Science & Technology. 2017;51(14):8196-8197.
  42. Mortazavi SMJ, Mortazavi SAR, Paknahad M. Evaluation of the Potential of Mobile Phone Specific Electromagnetic Fields (Umts) to Produce Micronuclei in Human Glioblastoma Cell Lines. Toxicol In Vitro. 2017;44:414-415. PMID: 28778768.
  43. Newman LA, Stark A, Chitale D, et al. Association between Benign Breast Disease in African American and White American Women and Subsequent Triple-Negtive Breast Cancer. JAMA Oncol. 2017;3(8):1102-1106.
  44. Nizovtseva EV, Todolli S, Olson WK, Studitsky VM. Towards Quantitative Analysis of Gene Regulation by Enhancers. Epigenomics. 2017. PMID: 28799793.
  45. Patt YZ, Murad W, Fekrazad MH, et al. Inst Ox-05-024: First Line Gemcitabine, Oxaliplatin, and Erlotinib for Primary Hepatocellular Carcinoma and Bile Duct Cancers: A Multicenter Phase Ii Trial. Cancer Med. 2017. PMID: 28801995.
  46. Prabhu VV, Lulla AR, Madhukar NS, et al. Cancer Stem Cell-Related Gene Expression as a Potential Biomarker of Response for First-in-Class Imipridone Onc201 in Solid Tumors. PLoS One. 2017;12(8):e0180541. PMID: 28767654. PMC5540272.
  47. Ramamurthy C, Chertock Y, Hall MJ. Randomized Controlled Trials in Hereditary Cancer Syndromes. Surgical Oncology Clinics of North America. 2017.
  48. Roussi P, Miller SM, Giri VN, et al. Effects of a Randomized Trial Comparing Standard and Enhanced Counseling for Men at High Risk of Prostate Cancer as a Function of Race and Monitoring Style. J Health Psychol. 2016:1359105316671188. PMID: 28810355. PMC5561513. NIHMS834324.
  49. Sakai K, Sanders KM, Youssef MR, et al. Role of Neurturin in Spontaneous Itch and Increased Nonpeptidergic Intraepidermal Fiber Density in a Mouse Model of Psoriasis. Pain. 2017. PMID: 28825602.
  50. Shah JJ, Kaufman JL, Zonder JA, et al. A Phase 1 and 2 Study of Filanesib Alone and in Combination with Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma. Cancer. 2017. PMID: 28817190.
  51. Shipley ST, Johnson DK, Roodgar M, et al. Mycobacterium Kansasii Isolated from Tuberculinpositive Rhesus Macaques (Macaca Mulatta) in the Absence of Disease. Comp Med. 2017;67(4):368-375. PMID: 28830585. PMC5557210.
  52. Simmons RA, Cosgrove SC, Romney MC, et al. Health Literacy: Cancer Prevention Strategies for Early Adults. Am J Prev Med. 2017;53(3s1):S73-s77. PMID: 28818249.
  53. Sultanov DC, Gerasimova NS, Kudryashova KS, et al. Unfolding of Core Nucleosomes by Parp-1 Revealed by Spfret Microscopy. AIMS Genet. 2017;4(1):21-31. PMID: 28804761. PMC5552189. NIHMS889070.
  54. Sznol M, Postow MA, Davies MJ, et al. Endocrine-Related Adverse Events Associated with Immune Checkpoint Blockade and Expert Insights on Their Management. Cancer Treat Rev. 2017;58:70-76. PMID: 28689073.
  55. Tan Y, Sementino E, Chernoff J, Testa JR. Targeting Myc Sensitizes Malignant Mesothelioma Cells to Pak Blockage-Induced Cytotoxicity. American Journal of Cancer Research. 2017;7(8):1724-1737.
  56. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2017: Clinical Practice Guidelines in Oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2017;15(8):1028-1061.
  57. Thompson MD, Lubet RA, McCormick DL, et al. Lack of Chemopreventive Efficacy of Metformin in Rodent Models of Urinary Bladder, Head and Neck, and Colon/Intestine Cancer. Oncology Letters. 2017;14(3):3480-3486.
  58. Troupes CD, Wallner M, Borghetti G, et al. Role of Stim1 (Stromal Interaction Molecule 1) in Hypertrophy-Related Contractile Dysfunction. Circ Res. 2017;121(2):125-136. PMID: 28592415. PMC5531450. NIHMS883225.
  59. Tursi SA, Lee EY, Medeiros NJ, et al. Bacterial Amyloid Curli Acts as a Carrier for DNA to Elicit an Autoimmune Response Via Tlr2 and Tlr9. PLoS Pathog. 2017;13(4):e1006315. PMID: 28410407. PMC5406031.
  60. Wang LS, Handorf EA, Wu H, Liu JC, Perlis CS, Galloway TJ. Surgery and Adjuvant Radiation for High-Risk Skin Adnexal Carcinoma of the Head and Neck. Am J Clin Oncol. 2017;40(4):429-432. PMID: 25599317. PMC4504824. NIHMS648261.
  61. Wang TP, Doss M, Tokar JL, Reddy S, Barta SK, Yu JQ. Lymphoma Causing Gastrosplenic Fistula Revealed by Fdg Pet/Ct. Clin Nucl Med. 2017. PMID: 28806244.
  62. Weng YL, An R, Cassin J, et al. An Intrinsic Epigenetic Barrier for Functional Axon Regeneration. Neuron. 2017;94(2):337-346.e336. PMID: 28426967.
  63. Xiao Q, Sherman SE, Wilner SE, et al. Janus Dendrimersomes Coassembled from Fluorinated, Hydrogenated, and Hybrid Janus Dendrimers as Models for Cell Fusion and Fission. Proc Natl Acad Sci U S A. 2017;114(34):E7045-e7053. PMID: 28784782.
  64. Xu B, Chakraborty H, Yadav VK, Zhang Z, Klein ML, Ren S. Tunable Two-Dimensional Interfacial Coupling in Molecular Heterostructures. Nat Commun. 2017;8(1):312. PMID: 28827651. PMC5567094.
  65. Xu J, Lee MH, Chakhtoura M, et al. Stat2 Is Required for Tlr-Induced Murine Dendritic Cell Activation and Cross-Presentation. J Immunol. 2016;197(1):326-336. PMID: 27233962. PMC4912940. NIHMS785183.
  66. Yadav RK, Jablonowski CM, Fernandez AG, et al. Histone H3g34r Mutation Causes Replication Stress, Homologous Recombination Defects and Genomic Instability in S. Pombe. eLife. 2017;6.
  67. Zaorsky NG, Lee CT, Zhang E, Keith SW, Galloway TJ. Hypofractionated Radiation Therapy for Basal and Squamous Cell Skin Cancer: A Meta-Analysis. Radiother Oncol. 2017. PMID: 28843727.
  68. Zhou G, Pantelopulos GA, Mukherjee S, Voelz VA. Bridging Microscopic and Macroscopic Mechanisms of P53-Mdm2 Binding with Kinetic Network Models. Biophys J. 2017;113(4):785-793. PMID: 28834715.

 

Staff Publications: July 2017

  1. Adams DL, Adams DK, He J, et al. Sequential Tracking of Pd-L1 Expression and Rad50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy. Clin Cancer Res. 2017. PMID: 28679765.
  2. Anthony S, Peterson JR, Ji Y. Use of Inosine Monophosphate Dehydrogenase Activity Assay to Determine the Specificity of Parp-1 Inhibitors. Methods Mol Biol. 2017;1608:337-342. PMID: 28695520.
  3. Arthur DW, Winter KA, Kuerer HM, et al. Nrg Oncology-Radiation Therapy Oncology Group Study 1014: 1-Year Toxicity Report from a Phase 2 Study of Repeat Breast-Preserving Surgery and 3-Dimensional Conformal Partial-Breast Reirradiation for in-Breast Recurrence. Int J Radiat Oncol Biol Phys. 2017;98(5):1028-1035. PMID: 28721885.
  4. Barta SK, Jain R, Mazumder A, et al. Pharmacokinetics-Directed Intravenous Busulfan Combined with High-Dose Melphalan and Bortezomib as a Conditioning Regimen for Patients with Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28684379.
  5. Bartel MJ, Srivastava A, Gordon S, Rothstein RI, Pohl H. Subsquamous Intestinal Metaplasia Is Common in Treatment-Naive Barrett’s Esophagus. Gastrointest Endosc. 2017. PMID: 28687439.
  6. Bazzoli A, Vance DJ, Rudolph MJ, et al. Using Homology Modeling to Interrogate Binding Affinity in Neutralization of Ricin Toxin by a Family of Single Domain Antibodies. Proteins. 2017. PMID: 28718923.
  7. Berger MJ, Ettinger DS, Aston J, et al. Nccn Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017;15(7):883-893. PMID: 28687576.
  8. Brennan MS, Barlotta RM, Simhan J. Frailty Assessments in Surgical Practice: What Is Frailty and How Can It Be Used in Prosthetic Health? Sexual Medicine Reviews. 2017.
  9. Brigle K, Rogers B. Pathobiology and Diagnosis of Multiple Myeloma. Seminars in Oncology Nursing. 2017.
  10. Bryan MS, Argos M, Andrulis IL, et al. Limited Influence of Germline Genetic Variation on All-Cause Mortality in Women with Early Onset Breast Cancer: Evidence from Gene-Based Tests, Single-Marker Regression, and Whole-Genome Prediction. Breast Cancer Research and Treatment. 2017;164(3):707-717.
    Burtness B, Powell M, Catalano P, et al. Randomized Phase Ii Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol. 2016;39(4):340-345. PMID: 24685886. PMC4177955. NIHMS572099.
  11. Cahn DB, Handorf EA, Ghiraldi EM, et al. Contemporary Use Trends and Survival Outcomes in Patients Undergoing Radical Cystectomy or Bladder-Preservation Therapy for Muscle-Invasive Bladder Cancer. Cancer. 2017. PMID: 28743162.
  12. Chernoff J, Radu M. Recent Advances in Methods to Assess the Activity of the Kinome. F1000Res. 2017;6.
  13. Cheung M, Testa JR. Bap1, a Tumor Suppressor Gene Driving Malignant Mesothelioma. Transl Lung Cancer Res. 2017;6(3):270-278. PMID: 28713672. PMC5504107.
  14. Chwistek M. Recent Advances in Understanding and Managing Cancer Pain. F1000Res. 2017;6:945. PMID: 28690839. PMC5482325.
  15. Cobb SC. Application Strategies and Tips for Using the Nursing Professional Development Practice Model. J Nurses Prof Dev. 2017;33(4):213-216. PMID: 28683039.
  16. Correa AF, Hrebinko RL, Smaldone MC. Management of Recurrent Venous Tumor Thrombus Following Inferior Vena Cava Thrombectomy: Is Surgery the Right Answer? Eur Urol Focus. 2016;2(6):631-632. PMID: 28723496. Editorial.
  17. Dasgupta Y, Koptyra M, Hoser G, et al. Normal Abl1 Is a Tumor Suppressor and Therapeutic Target in Human and Mouse Leukemias Expressing Oncogenic Abl1 Kinases. Blood. 2016;127(17):2131-2143. PMID: 26864341. PMC4850868.
  18. Deng N, Hoyte A, Mansour YE, et al. Allosteric Hiv-1 Integrase Inhibitors Promote Aberrant Protein Multimerization by Directly Mediating Inter-Subunit Interactions: Structural and Thermodynamic Modeling Studies. Protein Sci. 2016;25(11):1911-1917. PMID: 27503276. PMC5079246.
  19. Dong Y, Ridge JA, Li T, et al. Long-Term Toxicities in 10-Year Survivors of Radiation Treatment for Head and Neck Cancer. Oral Oncol. 2017;71:122-128. PMID: 28688679.
  20. Ebersole B, Soni RS, Moran K, Lango M, Devarajan K, Jamal N. The Role of Occupational Voice Demand and Patient-Rated Impairment in Predicting Voice Therapy Adherence. J Voice. 2017. PMID: 28709763.
  21. Edelman MJ, Wang X, Hodgson L, et al. Phase Iii Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer with Cyclooxygenase-2 Overexpression: Calgb 30801 (Alliance). Journal of Clinical Oncology. 2017;35(19):2184-2192. PMID:
  22. Egleston BL, Uzzo RG, Wong YN. Latent Class Survival Models Linked by Principal Stratification to Investigate Heterogenous Survival Subgroups among Individuals with Early-Stage Kidney Cancer. Journal of the American Statistical Association. 2017;112(518):534-546. PMID:
  23. El-Deiry WS, Taylor B, Neal JW. Tumor Evolution, Heterogeneity, and Therapy for Our Patients with Advanced Cancer: How Far Have We Come? Am Soc Clin Oncol Educ Book. 2017;37:e8-e15. PMID: 28746017.
  24. Epperla N, Maddocks KJ, Salhab M, et al. C-Myc-Positive Relapsed and Refractory, Diffuse Large B-Cell Lymphoma: Impact of Additional “Hits” and Outcomes with Subsequent Therapy. Cancer. 2017. PMID: 28749548.
  25. Ghatalia P, Nagarathinam R, Cooper H, Geynisman DM, El-Deiry WS. Mismatch Repair Deficient Metastatic Colon Cancer and Urothelial Cancer: A Case Report of Sequential Immune Checkpoint Therapy. Cancer Biol Ther. 2017:0. PMID: 28726535.
  26. Gilbert EA, Krafty RT, Bleicher RJ, Egleston BL. On the Use of Summary Comorbidity Measures for Prognosis and Survival Treatment Effect Estimation. Health Services and Outcomes Research Methodology. 2017:1-19.
  27. Gore JL, du Plessis M, Santiago-Jimenez M, et al. Decipher Test Impacts Decision Making among Patients Considering Adjuvant and Salvage Treatment after Radical Prostatectomy: Interim Results from the Multicenter Prospective Pro-Impact Study. Cancer. 2017;123(15):2850-2859.
  28. Gutierrez Diez PJ, Su Y, Russo J. Immunocytochemical Stem Cell Markers Can Predict Clinical Stage of Breast Cancer. Oncol Rep. 2017. PMID: 28714035.
  29. Haifler M, Kutikov A. Harnessing Proteinuria as a Predictor of Postsurgical Outcomes in Kidney Cancer Patients. Eur Urol Focus. 2016;2(6):623-624. PMID: 28723494.
  30. Hammers HJ, Plimack ER, Infante JR, et al. Safety and Efficacy of Nivolumab in Combination with Ipilimumab in Metastatic Renal Cell Carcinoma: The Checkmate 016 Study. J Clin Oncol. 2017:Jco2016721985. PMID: 28678668.
  31. Harper MG, Maloney P, Cobb SC. Application Strategies and Tips for Using the Nursing Professional Development Practice Model. J Nurses Prof Dev. 2017;33(4):213-216.
  32. Heinrich MC, Rankin C, Blanke CD, et al. Correlation of Long-Term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors with Next-Generation Sequencing Results Analysis of Phase 3 Swog Intergroup Trial S0033. JAMA Oncol. 2017;3(7):944-952.
  33. Henry KA, Swiecki-Sikora AL, Stroup AM, Warner EL, Kepka D. Area-Based Socioeconomic Factors and Human Papillomavirus (Hpv) Vaccination among Teen Boys in the United States. BMC Public Health. 2017;18(1):19. PMID: 28709420. PMC5513319.
  34. Hernandez-Borrero LJ, Zhang S, Lulla A, Dicker DT, El-Deiry WS. Cb002, a Novel P53 Tumor Suppressor Pathway-Restoring Small Molecule Induces Tumor Cell Death through the Pro-Apoptotic Protein Noxa. Cell Cycle. 2017:0. PMID: 28749203.
  35. Hooper R, Zaidi MR, Soboloff J. The Heterogeneity of Store-Operated Calcium Entry in Melanoma. Sci China Life Sci. 2016;59(8):764-769. PMID: 27417567. PMC4991353. NIHMS810145.
  36. Huang F, Goyal N, Sullivan K, et al. Targeting Brca1- and Brca2-Deficient Cells with Rad52 Small Molecule Inhibitors. Nucleic Acids Res. 2016;44(9):4189-4199. PMID: 26873923. PMC4872086.
  37. Hussaini A, Olszanski AJ, Stein CA, Bosch B, Nemeth P. Impact of an Alternative Steroid on the Relative Bioavailability and Bioequivalence of a Novel Versus the Originator Formulation of Abiraterone Acetate. Cancer Chemother Pharmacol. 2017. PMID: 28695267.
  38. Infante JR, Cohen RB, Kim KB, et al. Erratum To: A Phase I Dose-Escalation Study of Selumetinib in Combination with Erlotinib or Temsirolimus in Patients with Advanced Solid Tumors. Invest New Drugs. 2017. PMID: 28676972.
  39. Ishii S, Ishii S, Suzuki S, et al. Population Dynamics of Electrogenic Microbial Communities in Microbial Fuel Cells Started with Three Different Inoculum Sources. Bioelectrochemistry. 2017;117:74-82. PMID:
  40. Jackson-Rose J, Del Monte J, Groman A, et al. Chemotherapy Extravasation: Establishing a National Benchmark for Incidence among Cancer Centers. Clin J Oncol Nurs. 2017;21(4):438-445. PMID: 28738039.
  41. Jamal N. Reflections on Patient-Centered Care: From the Perspective of a Young Otolaryngologist. Otolaryngol Head Neck Surg. 2017:194599817721455. PMID: 28719758.
  42. Ji Y. Approaches for Investigating Translational Regulation Controlled by Parp1: Biotin-Based Uv Cross-Linking and Luciferase Reporter Assay. Methods Mol Biol. 2017;1608:201-210. PMID: 28695512.
  43. Jiang P, Li Y, Poleshko A, et al. The Protein Encoded by the Ccdc170 Breast Cancer Gene Functions to Organize the Golgi-Microtubule Network. EBioMedicine. 2017. PMID: 28687497.
  44. Joshi S, Kutikov A. Understanding Mutational Drivers of Risk: An Important Step toward Personalized Care for Patients with Renal Cell Carcinoma. Eur Urol Focus. 2016. PMID: 28753782.
  45. Kang B, Yang W, Lee S, et al. Precisely Tuneable Energy Transfer System Using Peptoid Helix-Based Molecular Scaffold. Sci Rep. 2017;7(1):4786. PMID: 28684782. PMC5500559.
  46. Kotova E, Tulin AV. High-Throughput Colorimetric Assay for Identifying Parp-1 Inhibitors Using a Large Small-Molecule Collection. Methods Mol Biol. 2017;1608:299-312. PMID: 28695517.
  47. Kutikov A. Surveillance of Small Renal Masses in Young Patients: A Viable Option in the Appropriate Candidate. Eur Urol Focus. 2016;2(6):567-568. PMID: 28723482.
  48. Lee Z, Waldorf BT, Cho EY, Liu JC, Metro MJ, Eun DD. Robotic Ureteroplasty with Buccal Mucosa Graft for the Management of Complex Ureteral Strictures. J Urol. 2017. PMID: 28736319.
  49. Li PD, Liu Z, Cheng TT, et al. Redox-Dependent Modulation of Metformin Contributes to Enhanced Sensitivity of Esophageal Squamous Cell Carcinoma to Cisplatin. Oncotarget. 2017. PMID: 28723636.
  50. Liu X, Li YS, Shinton SA, et al. Zebrafish B Cell Development without a Pre-B Cell Stage, Revealed by Cd79 Fluorescence Reporter Transgenes. J Immunol. 2017. PMID: 28739882.
  51. MacFarlane AWI, Jillab M, Smith MR, et al. Nk Cell Dysfunction in Chronic Lymphocytic Leukemia Is Associated with Loss of the Mature Cells Expressing Inhibitory Killer Cell Ig-Like Receptors. OncoImmunology. 2017.
  52. Makhov P, Naito S, Kolenko VM. Testing Parp Inhibitors Using a Murine Xenograft Model. Methods Mol Biol. 2017;1608:313-320. PMID: 28695518.
  53. Milora KA, Uppalapati SR, Sanmiguel JC, Zou W, Jensen LE. Interleukin-36beta Provides Protection against Hsv-1 Infection, but Does Not Modulate Initiation of Adaptive Immune Responses. Sci Rep. 2017;7(1):5799. PMID: 28724920. PMC5517484.
  54. Modi V, Xu Q, Adhikari S, Dunbrack RL, Jr. Assessment of Template-Based Modeling of Protein Structure in Casp11. Proteins. 2016;84 Suppl 1:200-220. PMID: 27081927. PMC5030193. NIHMS778467.
  55. Mortazavi SAR, Mortazavi G, Mortazavi SMJ. Comments on “Radiofrequency Electromagnetic Fields and Some Cancers of Unknown Etiology: An Ecological Study”. Sci Total Environ. 2017;609:1. PMID: 28732291.
  56. Mortazavi SAR, Mortazavi G, Mortazavi SMJ. Use of Cell Phones and Brain Tumors: A True Association? Neurol Sci. 2017. PMID: 28689225.
  57. Mortazavi SMJ, Mortazavi G, Paknahad M. Comment on Giuseppe Genchi Et Al. Mercury Exposure and Heart Diseases. Int. J. Environ. Res. Public Health 2017, 14, 74. Int J Environ Res Public Health. 2017;14(7). PMID: 28684671.
  58. Muffly L, Pasquini MC, Martens M, et al. Increasing Use of Allogeneic Hematopoietic Cell Transplantation in Patients Age 70 Years and Older in the United States. Blood. 2017. PMID: 28674027.
  59. Mukherjee K, Sha X, Magimaidas A, et al. Gadd45a Deficiency Accelerates Bcr-Abl Driven Chronic Myelogenous Leukemia. Oncotarget. 2017;8(7):10809-10821. PMID: 28086219. PMC5355225.
  60. O’Donnell MR, Tallman MS, Abboud CN, et al. Acute Myeloid Leukemia, Version 3.2017: Clinical Practice Guidelines in Oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2017;15(7):926-957.
  61. Parsaei H, Faraz M, Mortazavi SMJ. A Multilayer Perceptron Neural Network-Based Model for Predicting Subjective Health Symptoms in People Living in the Vicinity of Mobile Phone Base Stations. Ecopsychology. 2017;9(2):99-105.
  62. Pazina T, James AM, MacFarlane AWI, et al. The Anti-Slamf7 Antibody Elotuzumab Mediates Nk Cell Activation through Both Cd16-Dependent and –Independent Mechanisms. OncoImmunology. 2017.
  63. Perez-Leal O, Barrero CA, Merali S. Pharmacological Stimulation of Nuclear Factor (Erythroid-Derived 2)-Like 2 Translation Activates Antioxidant Responses. J Biol Chem. 2017. PMID: 28684421.
  64. Pollack A, Kwon D, Walker G, et al. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated with Radiotherapy for Prostate Cancer. J Natl Cancer Inst. 2017;109(2):1-8. PMID: 28376214.
  65. Radu M, Chernoff J. Recent Advances in Methods to Assess the Activity of the Kinome. F1000Res. 2017;6:1004. PMID: 28713564. PMC5490475.
  66. Ramamurthy C, Doyle J, Uzzo RG, Kutikov A, Smaldone MC, Geynisman DM. Role of Collaboration between Urologists and Medical Oncologists in the Advanced Prostate Cancer Space. Urol Oncol. 2017. PMID: 28720409. Editorial.
  67. Richardson C, Zhang S, Hernandez Borrero LJ, El-Deiry WS. Small-Molecule Cb002 Restores P53 Pathway Signaling and Represses Colorectal Cancer Cell Growth. Cell Cycle. 2017:0. PMID: 28749206.
  68. Ristau BT, Kutikov A, Uzzo RG, Smaldone MC. Active Surveillance for Small Renal Masses: When Less Is More. Eur Urol Focus. 2016;2(6):660-668. PMID: 28723504.
  69. Ristau BT, Manola J, Haas NB, et al. Retroperitoneal Lymphadenectomy in High-Risk Non-Metastatic Renal Cell Carcinoma: An Analysis of the Assure (Ecog-Acrin 2805) Adjuvant Trial. J Urol. 2017. PMID: 28728992.
  70. Shastri A, Budhathoki A, Barta SK, et al. Stimulation of Adrenergic Activity by Desipramine Enhances Hematopoietic Stem and Progenitor Cell Mobilization Along with G-Csf in Multiple Myeloma: A Pilot Study. Am J Hematol. 2017. PMID: 28675459.
  71. Stepanova DS, Semenova G, Kuo YM, et al. An Essential Role for the Tumor Suppressor Merlin in Regulating Fatty Acid Synthesis. Cancer Res. 2017. PMID: 28729415.
  72. Sznol M, Postow MA, Davies MJ, et al. Endocrine-Related Adverse Events Associated with Immune Checkpoint Blockade and Expert Insights on Their Management. Cancer Treat Rev. 2017;58:70-76. PMID: 28689073.
  73. Thomas C, Kotova E, Tulin AV. Parp-1 Interaction with and Activation by Histones and Nucleosomes. Methods Mol Biol. 2017;1608:255-267. PMID: 28695515.
  74. Van Cleave JH, Egleston BL, Brosch S, et al. Policy Research Challenges in Comparing Care Models for Dual-Eligible Beneficiaries. Policy Polit Nurs Pract. 2017:1527154417721909. PMID: 28735567.
  75. Wang LS, Handorf EA, Ridge JA, et al. Lymph-Node-Positive Cutaneous Nonmelanoma Skin Cancer: A Poor-Prognosis Disease in Need of Treatment Intensification. Ear, Nose and Throat Journal. 2017;96(7).
  76. Wei S, Al-Saleem T. The Pathology and Molecular Genetics of Sarcomatoid Renal Cell Carcinoma: A Mini-Review. J Kidney Cancer VHL. 2017;4(2):19-23. PMID: 28725540. PMC5515895.
  77. Williams NL, Dan T, Zaorsky NG, Garg S, Den RB. The Role of Genomic Techniques in Predicting Response to Radiation Therapy. ONCOLOGY (United States). 2017;31(7):1-11.
  78. Winckworth-Prejsnar K, Lentz LK, Nardi EA, Pruthi S, Fitzgerald CL, Carlson RW. Value Tools for Patients in Cancer Care. J Natl Compr Canc Netw. 2017;15(7):872-877. PMID: 28687575.
  79. Winkels RM, Sturgeon KM, Kallan MJ, et al. The Women in Steady Exercise Research (Wiser) Survivor Trial: The Innovative Transdisciplinary Design of a Randomized Controlled Trial of Exercise and Weight-Loss Interventions among Breast Cancer Survivors with Lymphedema. Contemp Clin Trials. 2017;61:63-72. PMID: 28739540.
  80. Yadav RK, Jablonowski CM, Fernandez AG, et al. Histone H3g34r Mutation Causes Replication Stress, Homologous Recombination Defects and Genomic Instability in S. Pombe. Elife. 2017;6. PMID: 28718400. PMC5515577.
  81. Yoo E, Cheng HA, Nardacci LE, et al. Activatable Interpolymer Complex-Superparamagnetic Iron Oxide Nanoparticles as Magnetic Resonance Contrast Agents Sensitive to Oxidative Stress. Colloids Surf B Biointerfaces. 2017;158:578-588. PMID: 28750340.

Staff Publications: June 2017

  1. Adelstein D, Gillison ML, Pfister DG, et al. Nccn Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Canc Netw. 2017;15(6):761-770. PMID: 28596256.
  2. Al-Ashmawy AAK, Ragab FA, Elokely KM, et al. Design, Synthesis and Sar of New-Di-Substituted Pyridopyrimidines as Atp-Competitive Dual Pi3kalpha/Mtor Inhibitors. Bioorg Med Chem Lett. 2017;27(14):3117-3122. PMID: 28571824.
  3. Alexander J, Cukierman E. Stromal Dynamic Reciprocity in Cancer: Intricacies of Fibroblastic-Ecm Interactions. Curr Opin Cell Biol. 2016;42:80-93. PMID: 27214794. PMC5064819. NIHMS786085.
  4. Alford RF, Leaver-Fay A, Jeliazkov JR, et al. The Rosetta All-Atom Energy Function for Macromolecular Modeling and Design. Journal of Chemical Theory and Computation. 2017;13(6):3031-3048.
  5. Ali N, Kutikov A, Geynisman DM. Resolution of a Debilitating Paraneoplastic Parkinson-Like Neurological Syndrome Following Tyrosine Inhibitor Therapy and Consolidative Nephrectomy in a Patient with Advanced Clear Cell Renal Cell Carcinoma. Urol Case Rep. 2017;14:18-20. PMID: 28660133. PMC5479944.
  6. Al-Khalifa SE, Jennings MC, Wuest WM, Minbiole KP. The Development of Next-Generation Pyridinium-Based Multiqac Antiseptics. ChemMedChem. 2017;12(4):280-283. PMID: 28033453.
  7. Blaauwgeers H, Flieder D, Warth A, et al. A Prospective Study of Loose Tissue Fragments in Non-Small Cell Lung Cancer Resection Specimens: An Alternative View to “Spread through Air Spaces”. Am J Surg Pathol. 2017. PMID: 28622180.
  8. Borgmann H, Katz MS, Catto J, Weight C, Kutikov A. Quantification of Urology Related Twitter Traffic Activity through a Standardized List of Social Media Communication Descriptors. Urology Practice. 2017;4(4):349-354.
  9. Carbone DP, Reck M, Paz-Ares L, et al. First-Line Nivolumab in Stage Iv or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376(25):2415-2426. PMID: 28636851.
  10. Choueiri TK, Plimack E, Arkenau HT, et al. Biomarker-Based Phase Ii Trial of Savolitinib in Patients with Advanced Papillary Renal Cell Cancer. J Clin Oncol. 2017:Jco2017722967. PMID: 28644771.
  11. De Bari B, Stish B, Ball MW, et al. Adult Prostatic Sarcoma: A Contemporary Multicenter Rare Cancer Network Study. Prostate. 2017;77(10):1160-1166. PMID: 28594087.
  12. Deihimi S, Lev A, Slifker M, et al. Brca2, Egfr, and Ntrk Mutations in Mismatch Repair-Deficient Colorectal Cancers with Msh2 or Mlh1 Mutations. Oncotarget. 2017;8(25):39945-39962. PMID: 28591715.
  13. Edelman MJ, Hu C, Le QT, et al. Randomized Phase Ii Study of Preoperative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage Iiia, N2+) Non-Small Cell Lung Cancer: Nrg Oncology Rtog 0839. J Thorac Oncol. 2017. PMID: 28629896.
  14. Erkmen CP, Mitchell M, Randhawa S, et al. An Enhanced Shared Decision Making Model to Address Willingness and Ability to Undergo Lung Cancer Screening and Follow-up Treatment in Minority Underserved Populations. J Community Health. 2017. PMID: 28612174.
  15. Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017;376(23):2211-2222. PMID: 28591523.
  16. Gallego-Villar L, Hannibal L, Haberle J, et al. Cysteamine Revisited: Repair of Arginine to Cysteine Mutations. J Inherit Metab Dis. 2017. PMID: 28643139.
  17. Ge Y, Kier BL, Andersen NH, Voelz VA. Computational and Experimental Evaluation of Designed Beta-Cap Hairpins Using Molecular Simulations and Kinetic Network Models. J Chem Inf Model. 2017. PMID: 28614661.
  18. Gokare P, El-Deiry WS. The Tuberous Sclerosis Complex Gets Fatter. Oncotarget. 2017;8(26):41780-41781. PMID: 28611315.
  19. Goldstein LJ, Zhao F, Wang M, et al. A Phase I/Ii Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Trastuzumab (Herceptin) in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Her2-Amplified Breast Cancer: A Trial of the Ecog-Acrin Cancer Research Group (E1104). Breast Cancer Res Treat. 2017. PMID: 28623430.
  20. Hahn NM, Bivalacqua TJ, Ross AE, et al. A Phase Ii Trial of Dovitinib in Bcg-Unresponsive Urothelial Carcinoma with Fgfr3 Mutations or Overexpression: Hoosier Cancer Research Network Trial Hcrn 12-157. Clinical Cancer Research. 2017;23(12):3003-3011.
  21. Hensley ML, Patel SR, von Mehren M, et al. Efficacy and Safety of Trabectedin or Dacarbazine in Patients with Advanced Uterine Leiomyosarcoma after Failure of Anthracycline-Based Chemotherapy: Subgroup Analysis of a Phase 3, Randomized Clinical Trial. Gynecol Oncol. 2017. PMID: 28651804.
  22. Herts BR, Silverman SG, Hindman NM, et al. Management of the Incidental Renal Mass on Ct: A White Paper of the Acr Incidental Findings Committee. J Am Coll Radiol. 2017. PMID: 28651987.
  23. Hou P, Wu C, Wang Y, et al. A Genome-Wide Crispr Screen Identifies Genes Critical for Resistance to Flt3 Inhibitor Ac220. Cancer Res. 2017. PMID: 28625976.
  24. Hurwitz MD, Harris J, Sartor O, et al. Adjuvant Radiation Therapy, Androgen Deprivation, and Docetaxel for High-Risk Prostate Cancer Postprostatectomy: Results of Nrg Oncology/Rtog Study 0621. Cancer. 2017;123(13):2489-2496.
  25. Jaffe EK. New Protein Structures Provide an Updated Understanding of Phenylketonuria. Mol Genet Metab. 2017. PMID: 28645531.
  26. Jamal N, Ebersole B, Erman A, Chhetri D. Maximizing Functional Outcomes in Head and Neck Cancer Survivors: Assessment and Rehabilitation. Otolaryngol Clin North Am. 2017. PMID: 28606600.
  27. Jiang W, Dulaimi E, Devarajan K, et al. Intratumoral Heterogeneity Analysis Reveals Hidden Associations between Protein Expression Losses and Patient Survival in Clear Cell Renal Cell Carcinoma. Oncotarget. 2017;8(23):37423-37434.
  28. Judd J, Zibelman M, Handorf E, et al. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. Oncologist. 2017. PMID: 28652280.
  29. Kim SP, Campbell SC, Gill I, et al. Collaborative Review of Risk Benefit Trade-Offs between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses. Eur Urol. 2017;72(1):64-75.
  30. Kruger WD. Cystathionine Beta-Synthase Deficiency: Of Mice and Men. Mol Genet Metab. 2017;121(3):199-205. PMID: 28583326.
  31. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for Brca1 and Brca2 Mutation Carriers. Jama. 2017;317(23):2402-2416. PMID: 28632866.
  32. Kuchenbaecker KB, McGuffog L, Barrowdale D, et al. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in Brca1 and Brca2 Mutation Carriers. J Natl Cancer Inst. 2017;109(7). PMID: 28376175. PMC5408990.
  33. Liu T, Kan XF, Ma C, et al. Gpx2 Overexpression Indicates Poor Prognosis in Patients with Hepatocellular Carcinoma. Tumour Biol. 2017;39(6):1010428317700410. PMID: 28635398.
  34. Lu W, Liu Y, Ma H, et al. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-D]Pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity. ACS Chem Neurosci. 2017. PMID: 28618224.
  35. Menzel LP, Chowdhury HM, Masso-Silva JA, et al. Potent in Vitro and in Vivo Antifungal Activity of a Small Molecule Host Defense Peptide Mimic through a Membrane-Active Mechanism. Sci Rep. 2017;7(1):4353. PMID: 28659617.
  36. Mortazavi SMJ, Mortazavi G, Paknahad M. Phase Down of Amalgam. Awareness of Minamata Convention among Jordanian Dentists. Saudi Medical Journal. 2017;38(5):560.
  37. Mortazavi SMJ, Mortazavi SAR. Auricular Hematoma Cases Caused by Mobile Phones. Oral and Maxillofacial Surgery Cases. 2017;3(3):54-55.
  38. Motzer RJ, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 2.2017: Clinical Practice Guidelines in Oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2017;15(6):804-834.
  39. Necchi A, Mariani L, Lo Vullo S, et al. Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-Based Analysis. European Urology Focus. 2017.
  40. Pal SK, Ali SM, Yakirevich E, et al. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma Via Comprehensive Genomic Profiling. Eur Urol. 2017. PMID: 28592388.
  41. Papadopoulos KP, Gluck L, Martin LP, et al. First-in-Human Study of Amg 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017. PMID: 28655795.
  42. Prinsep MR, Appleton TG, Hanson GR, et al. Tolyporphin Macrocycles from the Cyanobacterium Tolypothrix Nodosa Selectively Bind Copper and Silver and Reverse Multidrug Resistance. Inorganic Chemistry. 2017;56(10):5577-5585.
  43. \Razavi AM, Delemotte L, Berlin JR, Carnevale V, Voelz VA. Molecular Simulations and Free-Energy Calculations Suggest Conformation-Dependent Anion Binding to a Cytoplasmic Site as a Mechanism for Na+/K+-Atpase Ion Selectivity. J Biol Chem. 2017. PMID: 28588025.
  44. Terry MB, Keegan THM, Houghton LC, et al. Pubertal Development in Girls by Breast Cancer Family History: The Legacy Girls Cohort. Breast Cancer Res. 2017;19(1):69. PMID: 28595647. PMC5465536.
  45. van Tuyn J, Jaber-Hijazi F, MacKenzie D, et al. Oncogene-Expressing Senescent Melanocytes Upregulate Mhc Class Ii, a Candidate Melanoma Suppressor Function. J Invest Dermatol. 2017. PMID: 28647344.
  46. Wang HH, Deng L, Wen QL, et al. Early Postoperative Radiotherapy Is Associated with Improved Outcomes over Late Postoperative Radiotherapy in the Management of Completely Resected (R0) Stage Iiia-N2 Non-Small Cell Lung Cancer. Oncotarget. 2017. PMID: 28599290.
  47. Williams RM, Tagai EK, Santos SLZ, Slade JL, Carter RL, Holt CL. The Role of Leadership Support in a Church-Based Cancer Education Implementation Study. J Relig Health. 2017. PMID: 28597333.
  48. Winckworth-Prejsnar K, Nardi EA, Lentz LK, Crawford JA, Fitzgerald CL, Carlson RW. Developments in Molecular Testing and Biosimilars. J Natl Compr Canc Netw. 2017;15(6):772-782. PMID: 28596257.
  49. Zaorsky NG, Davis BJ, Nguyen PL, et al. The Evolution of Brachytherapy for Prostate Cancer. Nat Rev Urol. 2017;14(7):415-439. PMID: 28664931.
  50. Zibelman M, Plimack ER. Integrating Immunotherapy into the Management of Renal Cell Carcinoma. J Natl Compr Canc Netw. 2017;15(6):841-847. PMID: 28596263.

Staff Publications: May 2017

Better late than never

  1. Aksoy MO, Kim V, Cornwell WD, et al. Secretion of the Endoplasmic Reticulum Stress Protein, Grp78, into the Balf Is Increased in Cigarette Smokers. Respir Res. 2017;18(1):78. PMID: 28464871. PMC5414124.
  2. Arora S, Huwe PJ, Sikder R, et al. Functional Analysis of Rare Variants in Mismatch Repair Proteins Augments Results from Computation-Based Predictive Methods. Cancer Biol Ther. 2017:0. PMID: 28494185.
  3. Baker N, Tong C, Simhan J. Reconstructive Management Options of Delayed Complications Following Bladder Outlet Surgery. Curr Urol Rep. 2017;18(4):27. PMID: 28247326.
  4. Benson AB, 3rd, D’Angelica MI, Abbott DE, et al. Nccn Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15(5):563-573. PMID: 28476736.
  5. Booij J, Dubroff J, Pryma D, et al. Diagnostic Performance of the Visual Reading of 123i-Ioflupane Spect Images When Assessed with or without Quantification in Patients with Movement Disorders or Dementia. J Nucl Med. 2017. PMID: 28473597.
  6. Brant JM, Rodgers BB, Gallagher E, Sundaramurthi T. Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management. Clin J Oncol Nurs. 2017;21(3):71-80. PMID: 28524907.
  7. Chang EI. Impact of Venous Outflow Tract on Survival of Osteocutaneous Free Fibula Flaps for Mandibular Reconstruction: A 14-Year Review. Head Neck. 2017. PMID: 28467662.
  8. Chu CS, Pfister DG. Opportunities and Challenges: Human Papillomavirus and Cancer. J Natl Compr Canc Netw. 2017;15(5s):726-729. PMID: 28515256.
  9. Chwistek M, Wolf M. Naloxone for Outpatients at Risk of Opioid Overdose #328. J Palliat Med. 2017;20(5):562-563.
  10. Cripe J, Handorf E, Brown J, Jain A, Rubin S, Mantia-Smaldone G. National Cancer Database Report of Lymphadenectomy Trends in Endometrial Cancer. Int J Gynecol Cancer. 2017. PMID: 28525495.
  11. Dickson A, Bailey CT, Karanicolas J. Optimal Allosteric Stabilization Sites Using Contact Stabilization Analysis. Journal of Computational Chemistry. 2017;38(15):1138-1146.
  12. Gallagher E, Rogers BB, Brant JM. Cancer-Related Pain Assessment: Monitoring the Effectiveness of Interventions. Clin J Oncol Nurs. 2017;21(3):8-12. PMID: 28524910.
  13. Ganti AK, Hirsch FR, Wynes MW, et al. Access to Cancer Specialist Care and Treatment in Patients with Advanced Stage Lung Cancer. Clin Lung Cancer. 2017. PMID: 28522158.
  14. Geynisman DM. Hope and Uncertainty in the Age of Miracles. J Palliat Med. 2017. PMID: 28520504.
  15. Geynisman DM, Plimack ER. Bending the Curve of Advanced Urothelial Carcinoma. J Oncol Pract. 2017;13(5):319-320. PMID: 28489979.
  16. Giroux V, Lento AA, Islam M, et al. Long-Lived Keratin 15+ Esophageal Progenitor Cells Contribute to Homeostasis and Regeneration. J Clin Invest. 2017;127(6):2378-2391. PMID: 28481227.
  17. Godwin JL, Jaggi S, Sirisena I, et al. Nivolumab-Induced Autoimmune Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient with Metastatic Lung Cancer. J Immunother Cancer. 2017;5:40. PMID: 28515940. PMC5433051.
  18. Gupta N, Brill JV, Canto M, et al. Aga White Paper: Training and Implementation of Endoscopic Image Enhancement Technologies. Clin Gastroenterol Hepatol. 2017;15(6):820-826. PMID: 28528939.
  19. Gupta S, Wang L, Kruger WD. The C.797 G>a (P.R266k) Cystathionine Beta-Synthase Mutation Causes Homocystinuria by Affecting Protein Stability. Hum Mutat. 2017. PMID: 28488385.
  20. Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin Lymphoma Version 1.2017. JNCCN Journal of the National Comprehensive Cancer Network. 2017;15(5):608-638. PMID:
  21. Jadhav RR, Santucci-Pereira J, Wang YV, et al. DNA Methylation Targets Influenced by Bisphenol a and/or Genistein Are Associated with Survival Outcomes in Breast Cancer Patients. Genes (Basel). 2017;8(5). PMID: 28505145. PMC5448018.
  22. Jayadevappa R, Chhatre S, Wong YN, et al. Comparative Effectiveness of Prostate Cancer Treatments for Patient-Centered Outcomes: A Systematic Review and Meta-Analysis (Prisma Compliant). Medicine (United States). 2017;96(18).
  23. Jennings MC, Forman ME, Duggan SM, Minbiole KPC, Wuest WM. Efflux Pumps May Not Be the Major Drivers of Qac Resistance in Methicillin-Resistant Staphylococcus Aureus. Chembiochem. 2017. PMID: 28510317.
  24. Jiang Z, Slater CM, Zhou Y, et al. Lincin, a Novel Nf90-Binding Long Non-Coding Rna, Is Overexpressed in Advanced Breast Tumors and Involved in Metastasis. Breast Cancer Res. 2017;19(1):62. PMID: 28558830.
  25. Johnson DK, Karanicolas J. Computational Screening and Design for Compounds That Disrupt Protein-Protein Interactions. Curr Top Med Chem. 2017. PMID: 28482793.
  26. Kennedy PTF, Litwin S, Dolman GE, Bertoletti A, Mason WS. Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks. Viruses. 2017;9(5). PMID: 28468285.
  27. Lawton CAF, Lin X, Hanks GE, et al. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of Nrg Oncology Rtog 9202. Int J Radiat Oncol Biol Phys. 2017;98(2):296-303. PMID: 28463149.
  28. Marcinkiewicz C, Gerstenhaber JA, Sternberg M, Lelkes PI, Feuerstein G. Bitistatin-Functionalized Fluorescent Nanodiamond Particles Specifically Bind to Purified Human Platelet Integrin Receptor Alphaiibbeta3 and Activated Platelets. Int J Nanomedicine. 2017;12:3711-3720. PMID: 28553109. PMC5440039.
  29. McIntosh AG, Li T, Ito T, et al. Wbc Associates with Readmission Following Cystectomy. Bladder Cancer. 2017;3(2):95-103. PMID: 28516154. PMC5409152.
  30. Meyer JE, Finnberg NK, Chen L, et al. Tissue Tgf-Beta Expression Following Conventional Radiotherapy and Pulsed Low-Dose-Rate Radiation. Cell Cycle. 2017:1-4. PMID: 28486014.
  31. Michael JV, Wurtzel JGT, Mao GF, et al. Platelet Microparticles Infiltrating Solid Tumors Transfer Mirnas That Suppress Tumor Growth. Blood. 2017. PMID: 28500171.
  32. Miller-Halegoua SM. Why Null Results Do Not Mean No Results: Negative Findings Have Implications for Policy, Practice, and Research. Transl Behav Med. 2017. PMID: 28497323.
  33. Mirkin KA, Hollenbeak CS, Mohamed A, Jia Y, El-Deiry WS, Messaris E. Impact of Perineural Invasion on Survival in Node Negative Colon Cancer. Cancer Biol Ther. 2017:0. PMID: 28475454.
  34. Modi V, Sankararamakrishnan R. Binding Affinity of Pro-Apoptotic Bh3 Peptides for the Anti-Apoptotic Mcl-1 and A1 Proteins: Molecular Dynamics Simulations of Mcl-1 and A1 in Complex with Six Different Bh3 Peptides. Journal of Molecular Graphics & Modelling. 2017;73:115-128.
  35. Mortazavi SMJ, Mortazavi G, Paknahad M. Comment on Sundseth Et Al. Global Sources and Pathways of Mercury in the Context of Human Health. Int. J. Environ. Res. Public Health 2017, 14, 105. Int J Environ Res Public Health. 2017;14(5). PMID: 28475133.
  36. Nieborowska-Skorska M, Sullivan K, Dasgupta Y, et al. Gene Expression and Mutation-Guided Synthetic Lethality Eradicates Proliferating and Quiescent Leukemia Cells. J Clin Invest. 2017;127(6):2392-2406. PMID: 28481221.
  37. Patel D, Antwi J, Koneru PC, et al. A New Class of Allosteric Hiv-1 Integrase Inhibitors Identified by Crystallographic Fragment Screening of the Catalytic Core Domain. J Biol Chem. 2016;291(45):23569-23577. PMID: 27645997. PMC5095411.
  38. Perez-Guijarro E, Day CP, Merlino G, Zaidi MR. Genetically Engineered Mouse Models of Melanoma. Cancer. 2017;123(S11):2089-2103. PMID: 28543694. PMC5445933. NIHMS857850.
  39. Peshkova IO, Fatkhullina AR, Mikulski Z, Ley K, Koltsova EK. Il-27r Signaling Controls Myeloid Cells Accumulation and Antigen-Presentation in Atherosclerosis. Sci Rep. 2017;7(1):2255. PMID: 28536468. PMC5442117.
  40. Post CB, Levy RM. Editorial Overview: Theory & Computation. Curr Opin Struct Biol. 2017;43:iv-vi. PMID: 28477855.
  41. Ramamurthy C, Godwin JL, Borghaei H. Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose? Curr Treat Options Oncol. 2017;18(6):33. PMID: 28534248.
  42. Reddy SS, Handorf B, Farma JM, Sigurdson ER. Trends with Neoadjuvant Radiotherapy and Clinical Staging for Those with Rectal Malignancies. World J Gastrointest Surg. 2017;9(4):97-102. PMID: 28503257. PMC5406733.
  43. Reese JB, Lepore SJ, Handorf E, Haythornthwaite JA. Emotional Approach Coping and Depressive Symptoms in Colorectal Cancer Patients: The Role of the Intimate Relationship. J Psychosoc Oncol. 2017:0. PMID: 28511030.
  44. Ross KC, Andrews AJ, Marion CD, Yen TJ, Bhattacharjee V. Identification of the Serine Biosynthesis Pathway as a Critical Component of Braf Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells. Mol Cancer Ther. 2017. PMID: 28500236.
  45. Saleh D, Najjar M, Zelic M, et al. Kinase Activities of Ripk1 and Ripk3 Can Direct Ifn-Beta Synthesis Induced by Lipopolysaccharide. J Immunol. 2017;198(11):4435-4447. PMID: 28461567.
  46. Sanchorawala V, Palladini G, Kukreti V, et al. A Phase 1/2 Study of the Oral Proteasome Inhibitor Ixazomib in Relapsed or Refractory Light-Chain (Al) Amyloidosis. Blood. 2017. PMID: 28550039.
  47. Scannell Bryan M, Argos M, Andrulis IL, et al. Limited Influence of Germline Genetic Variation on All-Cause Mortality in Women with Early Onset Breast Cancer: Evidence from Gene-Based Tests, Single-Marker Regression, and Whole-Genome Prediction. Breast Cancer Res Treat. 2017. PMID: 28503721.
  48. Schott AF, Goldstein L, Cristofanilli M, et al. Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with Her-2 Negative Metastatic Breast Cancer (Mbc). Clin Cancer Res. 2017. PMID: 28539464.
  49. Schrock AB, Li SD, Frampton GM, et al. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. Journal of Thoracic Oncology. 2017;12(6):932-942.
  50. Semenova G, Stepanova DS, Dubyk C, et al. Targeting Group I P21-Activated Kinases to Control Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis. Oncogene. 2017. PMID: 28534510.
  51. Shaikh T, Meyer JE, Horwitz EM. Optimal Use of Combined Modality Therapy in the Treatment of Esophageal Cancer. Surgical Oncology Clinics of North America. 2017.
  52. Skala E, Sitarek P, Toma M, et al. Inhibition of Human Glioma Cell Proliferation by Altered Bax/Bcl-2-P53 Expression and Apoptosis Induction by Rhaponticum Carthamoides Extracts from Transformed and Normal Roots. J Pharm Pharmacol. 2016;68(11):1454-1464. PMID: 27696406.
  53. Skalka A. Finding, Conducting, and Nurturing Science: A Virologist’s Memoir. Annu Rev Virol. 2017. PMID: 28548882.
  54. Solinski AE, Koval AB, Brzozowski RS, et al. Diverted Total Synthesis of Carolacton-Inspired Analogs Yields Three Distinct Phenotypes in Streptococcus Mutans Biofilms. J Am Chem Soc. 2017;139(21):7188-7191. PMID: 28502178.
  55. Tahrir FG, Knezevic T, Gupta MK, et al. Evidence for the Role of Bag3 in Mitochondrial Quality Control in Cardiomyocytes. J Cell Physiol. 2017;232(4):797-805. PMID: 27381181.
  56. Tahrir FG, Shanmughapriya S, Ahooyi TM, et al. Dysregulation of Mitochondrial Bioenergetics and Quality Control by Hiv-1 Tat in Cardiomyocytes. J Cell Physiol. 2017. PMID: 28493473.
  57. Upton JW, Shubina M, Balachandran S. Ripk3-Driven Cell Death During Virus Infections. Immunol Rev. 2017;277(1):90-101. PMID: 28462524.
  58. Wagner J, Kline CL, Ralff MD, et al. Preclinical Evaluation of the Imipridone Family, Analogues of Clinical Stage Anti-Cancer Small Molecule Onc201, Reveals Potent Anti-Cancer Effects of Onc212. Cell Cycle. 2017:0. PMID: 28489985.
  59. Waingankar N, Esnaola NF, Uzzo RG. A Structured Framework for Optimizing Surgical Quality through Process-of-Care Trials. Urologic Oncology-Seminars and Original Investigations. 2017;35(5):177-179.
  60. Weitzner BD, Jeliazkov JR, Lyskov S, et al. Modeling and Docking of Antibody Structures with Rosetta. Nat Protoc. 2017;12(2):401-416. PMID: 28125104.
  61. Yadav VK, Klein ML. Probing the Dynamics of N-Methylacetamide in Methanol Via Ab Initio Molecular Dynamics. Phys Chem Chem Phys. 2017;19(20):12868-12875. PMID: 28470307.
  62. Zhang J, Zhou L, Zhao S, Dicker DT, El-Deiry WS. The Cdk4/6 Inhibitor Palbociclib Synergizes with Irinotecan to Promote Colorectal Cancer Cell Death under Hypoxia. Cell Cycle. 2017:1-8. PMID: 28486050.
  63. Zhou C, Martinez E, Di Marcantonio D, et al. Jun Is a Key Transcriptional Regulator of the Unfolded Protein Response in Acute Myeloid Leukemia. Leukemia. 2017;31(5):1196-1205.

Staff Publications: April 2017

  1. Aggarwal C, Borghaei H. Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. The Oncologist. 2017. PMID: 28408617.
  2. Allen RA, Jennings MC, Mitchell MA, Al-Khalifa SE, Wuest WM, Minbiole KPC. Ester- and Amide-Containing Multiqacs: Exploring Multicationic Soft Antimicrobial Agents. Bioorganic & Medicinal Chemistry Letters. 2017;27(10):2107-2112. PMID: 28392192.
  3. Bauman JE, Cohen E, Ferris RL, et al. Immunotherapy of Head and Neck Cancer: Emerging Clinical Trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017;123(7):1259-1271. PMID: 27906454.
  4. Beck TN, Young NG, Erickson ML, Prats I. Rare Antibody-Associated Hemolytic Transfusion Reaction and Transfusion-Related Acute Lung Injury: A Case Report. BMC Surgery. 2017;17(1):48. PMID: 28441942. PMC5405478.
  5. Benson AB, III, Venook AP, Cederquist L, et al. Colon Cancer, Version 1.2017: Clinical Practice Guidelines in Oncology. JNCCN. 2017;15(3):370-398. PMID:28275037.
  6. Boushra M, Tous S, Fetih G, et al. Development and Evaluation of Viscosity-Enhanced Nanocarrier (Ven) for Oral Insulin Delivery. International Journal of Pharmaceutics. 2016;511(1):462-472. PMID: 27418563.
  7. Brzozowski RS, Wuest WM. Twelve-Membered Macrolactones: Privileged Scaffolds for the Development of New Therapeutics. Chemical Biology & Drug Design. 2017;89(2):169-191. PMID: 27153932.
  8. Cagney DN, Martin AM, Catalano PJ, et al. Incidence and Prognosis of Patients with Brain Metastases at Diagnosis of Systemic Malignancy: A Population-Based Study. Neuro-oncology. 2017. PMID: 28444227.
  9. Carraro M, Minervini G, Giollo M, et al. Performance of in Silico Tools for the Evaluation of P16ink4a (Cdkn2a) Variants in Cagi. Human Mutation. 2017. PMID: 28440912.
  10. Chang HW, Studitsky VM. Chromatin Replication: Transmitting the Histone Code. Journal of nature and science. 2017;3(2). PMID: 28393112. PMC5384335.
    Chatare VK, Andrade RB. Total Synthesis of (-)-Albocycline. Angewandte Chemie (International ed in English). 2017. PMID: 28429505.
  11. Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and Paclitaxel-Carboplatin Chemotherapy and Secondary Cytoreduction in Recurrent, Platinum-Sensitive Ovarian Cancer (Nrg Oncology/Gynecologic Oncology Group Study Gog-0213): A Multicentre, Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology. 2017. PMID: 28438473.
  12. Darlow S, Heckman C. Results from a Tailored Sms and Behavior-Tracking Pilot Study on Sun-Safe Behaviors in Young Women. Health Education & Behavior. 2017:1090198117699507. PMID: 28363246.
  13. Deneka AY, Haber L, Kopp MC, Gaponova AV, Nikonova AS, Golemis EA. Tumor-Targeted Sn38 Inhibits Growth of Early Stage Non-Small Cell Lung Cancer (Nsclc) in a Kras/P53 Transgenic Mouse Model. PLoS One. 2017;12(4):e0176747. PMID: 28453558.
  14. Dias MF, Blumenstein R, Russo J. Use of Laser Capture Microdissection Allows Detection of Loss of Heterozygosity in Chromosome 9p in Breast Cancer. Oncology Letters. 2017;13(5):3831-3836.
  15. Escudier B, Motzer RJ, Sharma P, et al. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in Checkmate 025. European Urology. 2017. PMID: 28410865.
  16. Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 5.2017: Clinical Practice Guidelines in Oncology. JNCCN. 2017;15(4):504-535. PMID: 28404761
  17. Flynn WF, Haldane A, Torbett BE, Levy RM. Inference of Epistatic Effects Leading to Entrenchment and Drug Resistance in Hiv-1 Protease. Molecular Biology and Evolution. 2017. PMID: 28369521.
  18. Gerson JN, Skariah S, Denlinger CS, Astsaturov I. Perspectives of Her2-Targeting in Gastric and Esophageal Cancer. Expert Opinion on Investigational Drugs. 2017;26(5):531-540. PMID: 28387541.
  19. Golan S, Johnson SC, Maurice MJ, et al. Safety and Early Effectiveness of Robot-Assisted Partial Nephrectomy for Large Angiomyolipomas. BJU International. 2017;119(5):755-760. PMID: 27988984
  20. Gordon RE, Zhang L, Yang ZJ. Restore the Brake on Tumor Progression. Biochemical Pharmacology. 2017. PMID: 28389227.
  21. Gore JL, Plessis MD, Santiago-Jimenez M, et al. Decipher Test Impacts Decision Making among Patients Considering Adjuvant and Salvage Treatment after Radical Prostatectomy: Interim Results from the Multicenter Prospective Pro-Impact Study. Cancer. 2017. PMID: 28422278.
  22. Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN Guidelines® Insights Breast Cancer, Version 1.2017: Featured Updates to the NCCN Guidelines. JNCCN. 2017;15(4):433-451. PMID: 28404755
  23. Haifler M, Kutikov A. Current Role of Renal Biopsy in Urologic Practice. The Urologic Clinics of North America. 2017;44(2):203-211. PMID: 28411912.
  24. Haldane A, Flynn WF, He P, Vijayan RS, Levy RM. Structural Propensities of Kinase Family Proteins from a Potts Model of Residue Co-Variation. Protein Science. 2016;25(8):1378-1384. PMID: 27241634. PMC4972195.
  25. Heckman CJ, Handorf EA, Darlow SD, Ritterband LM, Manne SL. An Online Skin Cancer Risk-Reduction Intervention for Young Adults: Mechanisms of Effects. Health Psychology. 2017;36(3):215-225. PMID: 27819460. PMCID: PMC5328853
  26. Infante JR, Cohen RB, Kim KB, et al. A Phase I Dose-Escalation Study of Selumetinib in Combination with Erlotinib or Temsirolimus in Patients with Advanced Solid Tumors. Investigational New Drugs. 2017. PMID: 28424891.
  27. Jiang W, Dulaimi E, Devarajan K, et al. Intratumoral Heterogeneity Analysis Reveals Hidden Associations between Protein Expression Losses and Patient Survival in Clear Cell Renal Cell Carcinoma. Oncotarget. 2017. PMID: 28445125.
  28. Joshi SS, Uzzo RG. Renal Tumor Anatomic Complexity: Clinical Implications for Urologists. The Urologic Clinics of North America. 2017;44(2):179-187. PMID: 28411910.
  29. Jung S, Allen N, Arslan AA, et al. Demographic, Lifestyle, and Other Factors in Relation to Antimullerian Hormone Levels in Mostly Late Premenopausal Women. Fertility and Sterility. 2017;107(4):1012-1022.e1012. PMID: 28366409.
  30. Klein-Szanto AJ, Bassi DE. Proprotein Convertase Inhibition: Paralyzing the Cell’s Master Switches. Biochemical Pharmacology. 2017. PMID: 28456517.
  31. Kumar SK, Callander NS, Alsina M, et al. Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology. JNCCN. 2017;15(2):230-+. PMID: 28188192
  32. Kutikov A, Smaldone MC. The Small Renal Mass and Its Management in Urologic Practice. The Urologic Clinics of North America. 2017;44(2):xvii. PMID: 28411925.
  33. Lawler AC, Ghiraldi EM, Tong C, Friedlander JI. Extracorporeal Shock Wave Therapy: Current Perspectives and Future Directions. Current Urology Reports. 2017;18(4). PMID: 28247327
  34. Lee HO, Uzzo RG, Kister D, Kruger WD. Combination of Serum Histidine and Plasma Tryptophan as a Potential Biomarker to Detect Clear Cell Renal Cell Carcinoma. Journal of Translational Medicine. 2017;15(1):72. PMID: 28385150. PMC5383954.
  35. Li PD, Hu JL, Ma C, et al. Upregulation of the Long Non-Coding Rna Pvt1 Promotes Esophageal Squamous Cell Carcinoma Progression by Acting as a Molecular Sponge of Mir-203 and Lasp1. Oncotarget. 2017. PMID: 28404954.
  36. Liederbach E, Kyrillos A, Wang CH, Liu JC, Sturgis EM, Bhayani MK. The National Landscape of Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma. International Journal of Cancer. 2017;140(3):504-512. PMID: 27667729.
  37. Longacre ML, Valdmanis VG, Handorf EA, Fang CY. Work Impact and Emotional Stress among Informal Caregivers for Older Adults. The Journals of Gerontology Series B, Psychological Sciences and Social Sciences. 2017;72(3):522-531. PMID: 27048567.
  38. Lupey-Green LN, Moquin SA, Martin KA, et al. Parp1 Restricts Epstein Barr Virus Lytic Reactivation by Binding the Bzlf1 Promoter. Virology. 2017;507:220-230. PMID: 28456021.
  39. Lynch SM, Mitra N, Ravichandran K, et al. Telomere Length and Neighborhood Circumstances: Evaluating Biological Response to Unfavorable Exposures. Cancer Epidemiology, Biomarkers & Prevention. 2017;26(4):553-560. PMID: 28373169.
  40. Meng Y, Cai KQ, Moore R, et al. Pten Facilitates Epiblast Epithelial Polarization and Proamniotic Lumen Formation in Early Mouse Embryos. Developmental Dynamics. 2017. PMID: 28387983.
  41. Miller MP, Kostakoglu L, Pryma D, et al. Reader Training for the Re-Staging of Biochemically Recurrent Prostate Cancer Using Fluciclovine (18f) Pet/Ct. Journal of Nuclear Medicine. 2017. PMID: 28385791.
  42. Moore KN, Borghaei H, O’Malley DM, et al. Phase 1 Dose-Escalation Study of Mirvetuximab Soravtansine (Imgn853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Patients with Solid Tumors. Cancer. 2017. PMID: 28440955.
  43. Moore KN, Martin LP, O’Malley DM, et al. Safety and Activity of Mirvetuximab Soravtansine (Imgn853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. Journal of Clinical Oncology. 2017; 35(10):1112-1118. PMID: 28029313
  44. Mortazavi SMJ, Zarei S, Taheri M, et al. Sensitivity to Antibiotics of Bacteria Exposed to Gamma Radiation Emitted from Hot Soils of the High Background Radiation Areas of Ramsar, Northern Iran. The International Journal of Occupational and Environmental Medicine. 2017;8(2):80-84. PMID: 28432369.
  45. Necchi A, Pond GR, Smaldone MC, et al. Robot-Assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-Invasive Bladder Cancer: The Oncologist’s Perspective from a Multicentre Study. European Urology Focus. 2017.
  46. Nizovtseva EV, Clauvelin N, Todolli S, et al. Nucleosome-Free DNA Regions Differentially Affect Distant Communication in Chromatin. Nucleic Acids Research. 2017;45(6):3059-3067. PMID: 27940560. PMCID: PMC5389534
  47. Obeid EI, Hall MJ, Daly MB. Multigene Panel Testing and Breast Cancer Risk: Is It Time to Scale Down? JAMA Oncology. 2017. PMID: 28418452.
  48. Pazina T, Shemesh A, Brusilovsky M, Porgador A, Campbell KS. Regulation of the Functions of Natural Cytotoxicity Receptors by Interactions with Diverse Ligands and Alterations in Splice Variant Expression. Frontiers in Immunology. 2017;8:369. PMID: 28424697. PMC5371597.
  49. Ragin C, Liu JC, Jones G, et al. Prevalence of HPV Infection in Racial-Ethnic Subgroups of Head and Neck Cancer Patients. Carcinogenesis. 2017;38(2):218-229.
  50. Ralff MD, Kline CLB, Kucukkase OC, et al. Onc201 Demonstrates Anti-Tumor Effects in Both Triple Negative and Non-Triple Negative Breast Cancers through Trail-Dependent and Trail-Independent Mechanisms. Molecular cancer therapeutics. 2017. PMID: 28424227.
  51. Reese JB, Beach MC, Smith KC, et al. Effective Patient-Provider Communication About Sexual Concerns in Breast Cancer: A Qualitative Study. Supportive Care in Cancer. 2017. PMID: 28451911.
  52. Ristau BT, Correa AF, Uzzo RG, Smaldone MC. Active Surveillance for the Small Renal Mass: Growth Kinetics and Oncologic Outcomes. The Urologic clinics of North America. 2017;44(2):213-222. PMID: 28411913.
  53. Ristau BT, Kutikov A, Uzzo RG, Smaldone MC. Active Surveillance for Small Renal Masses: When Less Is More. European Urology Focus. 2017.
  54. Roche LM, Niu X, Stroup AM, Henry KA. Disparities in Female Breast Cancer Stage at Diagnosis in New Jersey: A Spatial-Temporal Analysis. JPHMP. 2016. PMID: 28430705.
  55. Saribas AS, Coric P, Hamazaspyan A, et al. Emerging from the Unknown: Structural and Functional Features of Agnoprotein of Polyomaviruses. Journal of Cellular Physiology. 2016;231(10):2115-2127. PMID: 26831433. PMC5217748.
  56. Segal S, John G, Sammel M, et al. Urinary Incontinence and Other Pelvic Floor Disorders after Radiation Therapy in Endometrial Cancer Survivors. Maturitas. 2017. PMID: 28396018.
  57. Smaldone MC, Egleston B, Hollingsworth JM, et al. Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data. Medical Care. 2017;55(4):398-404. PMID: 27820596. PMCID: PMC5352513.
  58. Soni RS, Ebersole B, Jamal N. Does Even Low-Grade Dysphonia Warrant Voice Center Referral? Journal of Voice. 2017. PMID: 28396220.
  59. Tong C, Daskalakis N, Edwards DC, Cahn DB, Belkoff L, Geynisman DM. Malignant Infiltration of the Penis from Urothelial Carcinoma of the Bladder. Urology. 2017. PMID: 28373110.
  60. Waldorf B, Lee Z, Kidd L, et al. Robotic Buccal Ureteroplasty: A Review of the Current Literature. Current Urology Reports. 2017;18(5):40. PMID: 28401476.
  61. Wei S, Layfield LJ, LiVolsi VA, Montone KT, Baloch ZW. Reporting of Fine Needle Aspiration (Fna) Specimens of Salivary Gland Lesions: A Comprehensive Review. Diagnostic Cytopathology. 2017. PMID: 28371507.
  62. Weidhaas JB, Harris J, Schaue D, et al. The Kras-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncology. 2017;3(4):483-491. PMID: 28006059.
  63. Weinberg DS, Lin JE, Foster NR, et al. Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. Cancer Prevention Research (Philadelphia, PA). 2017. PMID: 28396341.
  64. Weng YL, An R, Cassin J, et al. An Intrinsic Epigenetic Barrier for Functional Axon Regeneration. Neuron. 2017;94(2):337-346.e336. PMID: 28426967.
  65. Whelan KA, Chandramouleeswaran PM, Tanaka K, et al. Autophagy Supports Generation of Cells with High Cd44 Expression Via Modulation of Oxidative Stress and Parkin-Mediated Mitochondrial Clearance. Oncogene. 2017. PMID: 28414310.
  66. Wierda WG, Zelenetz AD, Gordon LI, et al. NCCN Guidelines® Insights Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured Updates to the NCCN Guidelines. JNCCN. 2017;15(3):293-311. PMID: 28275031
  67. Xi H, Zhang Y, Xu Y, et al. Caspase-1 Inflammasome Activation Mediates Homocysteine-Induced Pyrop-Apoptosis in Endothelial Cells. Circulation research. 2016;118(10):1525-1539. PMID: 27006445. PMC4867131.
  68. Xu Q, Tang Q, Katsonis P, et al. Benchmarking Predictions of Allostery in Liver Pyruvate Kinase in Cagi4. Human Mutation. 2017. PMID: 28370845.
  69. Xue J, McKay JD, Grimm J, et al. Small-Field Dose Measurements Using Plastic Scintillation Detector in Heterogeneous Media. Medical physics. 2017. PMID: 28398596.
  70. Yoo SK, Ahmed AA, Ileto J, et al. Industry Funding among Leadership in Medical Oncology and Radiation Oncology in 2015. International Journal of Radiation Oncology, Biology, Physics. 2017. PMID: 28366578.
  71. Younes A, Hilden P, Coiffier B, et al. International Working Group Consensus Response Evaluation Criteria in Lymphoma (Recil 2017). Annals of Oncology. 2017. PMID: 28379322.
  72. Zaorsky NG, Churilla TM, Egleston BL, et al. Causes of Death among Cancer Patients. Annals of Oncology. 2017;28(2):400-407.

Two things of note. If your research was funded, in full or in part, by the Core Grant you must acknowledge the Core Grant in your paper. For examples of how to acknoweldge grant funding from the NIH, NSF, HHS, and other grantors see the Acknowledging Grant Funding tab of our NIH Public Access Compliance guide. Finally, unless the publisher deposits articles with the NIHMS (NIH Manuscript Submission System) for inclusion in PubMed Central, the primary author (or designated delegate) is responsible for depositing the final approved manuscript and all tables and images with the NIHMS. Do not deposit the publisher’s PDF with the NIHMS, as that is the publisher’s property. Elsevier, Wiley, JAMA, BMJ may deposit their PDFs as they see fit, you the author, however, may not. For instructions on how to deposit a manuscript with the NIHMS, see the NIH Public Access Compliance guide.